Immunotherapeutic nitriles

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

548472, 548479, 546142, 514417, 514416, 514309, C07D20948, C07D20946, C07D21724, A61K 3140

Patent

active

057288453

ABSTRACT:
Novel nitriles are inhibitors of tumor necrosis factor .alpha. and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3-Phthalimido-3-(3,4-dimethoxyphenyl)propionitrile.

REFERENCES:
patent: 5512682 (1996-04-01), Hilpert
David Cavalla, et al., "Phosphodiesterase IV Inhibitors: Structural Diversity and Therapeutic Potential In Asthma", Current Medical Chemistry, 1995, 2, pp. 561-572.
Louis J. Lombardo, "Phosphodiesterase-IV Inhibitors: Novel Therapeutics for the Treatment of Inflammatory Diseases", Current Pharmaceutical Design, 1995, pp. 255-268.
John A. Lowe, III, et al., "The PDE IV family of calcium-independent phosphodiesterase enzymes", Drugs of the Future, 1992, 17(9): 799-807.
Malcolm N. Palfreyman, "Phosphodiesterase type IV inhibitors as antiinflammatory agents", Drugs of the Future, 1995, 20(8): 793-804.
Les Sekut, et al., "Pathophysiology and Regulation of TNF-.alpha. in Inflammation", DN&P, 9(5), Jun. 1996, pp. 261-269.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Immunotherapeutic nitriles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapeutic nitriles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapeutic nitriles will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-958905

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.